Molecular Partners

Molecular Partners is a dynamic biotechnology research company focused on pioneering DARPin therapeutics, representing a novel class of custom-built drugs designed to address complex medical challenges. With a strong commitment to innovation, Molecular Partners is dedicated to providing unique solutions to patients through its proprietary programs and strategic partnerships with leading pharmaceutical companies. Molecular Partners operates with a clear vision of advancing healthcare and improving patient outcomes.

Located at Wagistrasse 14, Schlieren-Zürich, Zürich Area 8952, CH, and with an additional office at 23 Bradford St, Suite 8, West Concord, Massachusetts 01742, US, Molecular Partners is strategically positioned to drive advancements in the biotechnology sector. The company’s main focus is in oncology, and it has several programs in various stages of pre-clinical and clinical development. Molecular Partners leverages the unique advantages of DARPins to create innovative therapies.

Molecular Partners continues to expand its capabilities and broaden its impact on the healthcare landscape. With a strong foundation in repeat proteins and protein engineering, Molecular Partners is dedicated to developing cutting-edge treatments for a wide range of medical conditions. We invite the management team at Molecular Partners to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.